Antimicrobial resistance of Escherichia coli in Mexico: How serious is the problem?

Authors

  • Joel Murillo Llanes Culiacan General Hospital, Sinaloa, Mexico
  • Joseph Varon The University of Texas Health Science Center at Houston, The University of Texas Medical Branch at Galveston and Houston, Texas, USA
  • Jesús Salvador Velarde Félix Genomic Medicine Center, Culiacan General Hospital, Culiacan, Sinaloa, Mexico
  • Fernando Pavel González-Ibarra Mount Sinai School of Medicine, Jersey City Medical Center, NJ, USA

DOI:

https://doi.org/10.3855/jidc.1525

Keywords:

Escherichia coli, antimicrobial resistance, hospital, patients

Abstract

Introduction: This study aimed to determine the resistance patterns of Escherichia coli (E. coli) in Mexico to several antibiotics and research some therapeutic options.

Methodology: Positive cultures for E. coli isolated from bronchial secretions, urine, central catheter, blood, and infected wounds in the Culiacan General Hospital, Sinaloa, Mexico from 30 June 2004 to 1 July 2007 were studied. Resistance against multiple antibiotics was measured and compared by gender and the hospital unit where the bacteria were isolated.

Results: In total, 1511 specimens were analyzed from men (45.4%) and women (54.5%), of which 251 were positive for E. coli. Antimicrobial resistance was highest in the neurosurgery service (58.4%). Samples included sputum (14.7%), bronchial secretions (17.9%), wounds (35.4%), urine/Foley catheter tip (35.5%), central catheter tips (5.6%), and blood cultures (7.2%). Resistance to ampicillin was highest at 91% followed by ciprofloxacin at 80.6%, trimethoprim-sulfamethoxazole at 70.2%, piperacillin/tazobactam at 14.4%, and imipenem at 6.8%.

Conclusions: Trimethoprim should not be recommended as an empiric option for E. coli infections and the benefit of quinolones is low. It is important to understand the resistance of the bacteria in each medical center, consider its frequency in each service within the same hospital, and take all necessary measures to ensure and create a clinical attitude of prevention.

Author Biographies

Joel Murillo Llanes, Culiacan General Hospital, Sinaloa, Mexico

Research Department

Joseph Varon, The University of Texas Health Science Center at Houston, The University of Texas Medical Branch at Galveston and Houston, Texas, USA

Clinical Professor of Medicine and Professor of Acute and Continuing Care

Jesús Salvador Velarde Félix, Genomic Medicine Center, Culiacan General Hospital, Culiacan, Sinaloa, Mexico

Genomic Medicine Center

Fernando Pavel González-Ibarra, Mount Sinai School of Medicine, Jersey City Medical Center, NJ, USA

Internal Medicine Department

Downloads

Published

2011-11-30

How to Cite

1.
Murillo Llanes J, Varon J, Velarde Félix JS, González-Ibarra FP (2011) Antimicrobial resistance of Escherichia coli in Mexico: How serious is the problem?. J Infect Dev Ctries 6:126–131. doi: 10.3855/jidc.1525

Issue

Vol. 6 No. 02: February 2012

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC